for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kalvista Pharmaceuticals Inc

KALV.OQ

Latest Trade

13.65USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.64

 - 

34.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.65
Open
--
Volume
--
3M AVG Volume
2.96
Today's High
--
Today's Low
--
52 Week High
34.65
52 Week Low
13.64
Shares Out (MIL)
17.82
Market Cap (MIL)
243.18
Forward P/E
-12.32
Dividend (Yield %)
--

Next Event

Kalvista Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Kalvista Pharmaceuticals Reports Qtrly Loss Per Share $0.42

Kalvista Pharma Says Martin Edwards Elected As Chair

Kalvista Pharmaceuticals Files For Offering Of Up To $50 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Industry

Biotechnology & Drugs

Contact Info

55 Cambridge Pkwy Ste 901E

+1.857.9990075

http://www.kalvista.com/

Executive Leadership

Thomas Andrew Crockett

Chief Executive Officer, Director

Benjamin L. Palleiko

Chief Financial Officer, Chief Business Officer

Andreas Maetzel

Senior Vice President, Medical

Edward P. Feener

Chief Scientific Officer

Christopher M. Yea

Chief Development Officer

Key Stats

1.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.530

2019

-1.380

2020(E)

-1.108
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.41
Price To Book (MRQ)
2.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-32.89
Return on Equity (TTM)
-26.05

Latest News

BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials

* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001

BRIEF-Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50

* KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals

* Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing Source text - http://bit.ly/2xTHJJO Further company coverage:

BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck

* Kalvista Pharmaceuticals announces collaboration with Merck

BRIEF-KalVista Pharmaceuticals reports Q1 loss per share of $0.51

* KalVista pharmaceuticals reports fiscal first quarter results

BRIEF-Kalvista Pharmaceuticals reports Q4 loss per share $0.43

* Kalvista Pharmaceuticals provides operational update and reports fiscal fourth quarter and full year financial results

BRIEF-Kalvista Pharmaceuticals enters into an at-market sales agreement with BTIG

* Kalvista Pharmaceuticals Inc - on July 13, 2017 co entered into an at--market sales agreement with BTIG, LLC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up